Supplementary Figure 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
<p>AR activities and NEPC signatures in ATM- and BRCA2- mutated tumors.</p>
Bewaard in:
Gelijkaardige items
-
Supplementary Figure 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
door: Justin Hwang (15925675)
Gepubliceerd in: (2025) -
Supplementary Figure 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
door: Justin Hwang (15925675)
Gepubliceerd in: (2025) -
Supplementary Table 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
door: Justin Hwang (15925675)
Gepubliceerd in: (2025) -
Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
door: Justin Hwang (15925675)
Gepubliceerd in: (2025) -
Supplementary Table 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
door: Justin Hwang (15925675)
Gepubliceerd in: (2025)